企業概要
United Therapeutics Corporation is engaged in the development and commercialization of products designed to address unmet medical needs for patients suffering from chronic and life-threatening diseases within the United States and internationally. The company operates within the Healthcare sector, specifically in the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical solutions rather than mass-market commodities. Its operational scale is defined by a market capitalization of $25.49B, an annual revenue of $3.18B, and an employee base of 1400 individuals. These valuation and revenue figures indicate that United Therapeutics holds a substantial position in its niche, commanding a significant market presence that reflects the high barriers to entry and specialized nature of the specialty drug manufacturing industry.
財務健全性
The company reported a revenue of $3.18B and net income of $1.33B, with EBITDA reaching $1.60B. The substantial gap between the revenue figure and the net income reveals a robust cost structure where operating expenses and taxes consume approximately 58.1% of total sales, yet the remaining profit remains highly concentrated. The free cash flow stands at $582.01M, which signifies strong financial flexibility allowing the firm to fund research, development, and potential acquisitions without relying heavily on external capital markets. Three distinct margin metrics further illustrate this efficiency: a gross margin of 87.9% demonstrates the high value and low variable cost of pharmaceutical products, an operating margin of 45.0% indicates effective control over overhead and administrative costs, and a profit margin of 41.9% confirms the exceptional ability to convert sales into net earnings. Regarding liquidity and leverage, the company holds $2.92B in cash against a minimal debt load of $37.60M, resulting in a debt-to-equity ratio of 0.53. This disparity indicates a highly conservative balance sheet with negligible leverage risk. Furthermore, a current ratio of 6.61 suggests that the company possesses more than six times the liquid assets necessary to cover its short-term obligations, pointing to an extremely secure short-term liquidity position. Return metrics show a return on equity of 19.7% and a return on assets of 12.4%, which reveal that management is generating high returns relative to the capital employed and the total asset base.
バリュエーション評価
Valuation multiples indicate the market's pricing expectations for future performance. The trailing twelve-month P/E ratio is 20.88, while the forward P/E is 17.09. The difference between these two metrics implies that the market expects earnings to grow in the future, as the price investors are willing to pay for next year's earnings is lower relative to current earnings. The price-to-book ratio stands at 3.58, indicating that the market values the company at a significant premium over its net asset book value, reflecting the intangible value of its intellectual property and brand. Alternative valuation metrics include a price-to-sales ratio of 8.01 and an EV/EBITDA of 14.12, which suggest that the company is valued high relative to its sales and operating cash generation, typical for high-growth biotech firms. Regarding price volatility and range, the 52-week high is $607.89 and the 52-week low is $266.98. Without a specific current share price provided in the facts, the valuation context is strictly bound by these historical trading extremes which define the recent price trajectory. The beta value is 0.75, which means the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations.
Growth & Income
Growth dynamics highlight the trajectory of the business model. Revenue growth year-over-year is 7.4%, while earnings growth year-over-year is 24.5%. The fact that earnings are growing at a rate more than three times faster than revenue implies significant operating leverage and efficiency improvements, as sales volume increases are translating disproportionately higher into bottom-line profit. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%. This indicates that the firm does not distribute earnings to shareholders but instead retains 100% of its profits to reinvest into research, development, and commercial expansion. Consequently, the overall growth and income profile is characterized by capital appreciation potential driven by reinvestment rather than current income generation, aligning with the growth strategy of specialty pharmaceutical companies that prioritize long-term pipeline development over immediate shareholder returns.